Atossa Genetics is preparing to start Phase II studies of both its oral and topical endoxifen formulations in Q218. Endoxifen, an estrogen receptor (ER) antagonist, is being advanced in topical form to treat high mammographic breast density (MBD), and also as an oral drug to prevent cancer recurrence in women refractory to tamoxifen. The company plans to raise $20m in equity through a rights offering in May 2018, which we believe should fund the Phase II endoxifen trials through completion.
26 Apr 2018
Atossa Genetics - Endoxifen to start Phase II studies shortly
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Atossa Genetics - Endoxifen to start Phase II studies shortly
Atossa Therapeutics, Inc. (ATOS:NAS) | 0 0 0.0%
- Published:
26 Apr 2018 -
Author:
Pooya Hemami -
Pages:
11
Atossa Genetics is preparing to start Phase II studies of both its oral and topical endoxifen formulations in Q218. Endoxifen, an estrogen receptor (ER) antagonist, is being advanced in topical form to treat high mammographic breast density (MBD), and also as an oral drug to prevent cancer recurrence in women refractory to tamoxifen. The company plans to raise $20m in equity through a rights offering in May 2018, which we believe should fund the Phase II endoxifen trials through completion.